One in ten Canadians with diabetes have kidney disease. With the emergence of data on the cardiorenal protective properties of GLP1 receptor agonists and SGLT2 inhibitors, we are moving into a new standard of care with a focus on renal health in addition to glycemic control.
In this expert brief, Dr. Sara Stafford and Dr. Jeff Winterstein discuss the relationship between type 2 diabetes and chronic kidney disease, and the evolution of treatment options for declining renal function, that takes us beyond the traditional use of ACEs and ARBs.
This program has received an unrestricted educational grant or in-kind support from Novo Nordisk.